1. Membrane Transporter/Ion Channel
  2. SGLT

Bexagliflozin (Synonyms: EGT1442; EGT0001442; THR-1442)

Cat. No.: HY-17604 Purity: 98.63%
Data Sheet SDS Handling Instructions

Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.

For research use only. We do not sell to patients.
Bexagliflozin Chemical Structure

Bexagliflozin Chemical Structure

CAS No. : 1118567-05-7

Size Price Stock Quantity
10 mM * 1 mL in DMSO $133 In-stock
2 mg $90 In-stock
5 mg $130 In-stock
10 mg $190 In-stock
25 mg $390 In-stock
50 mg $590 In-stock
100 mg $890 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. target: SGLT2 IC50: 5.6 μM (SGLT1)/ 2 nM (SGLT2) 1) In normal rats and dogs a saturable urinary glucose excretion was produced with an ED50 of 0.38 and 0.09 mg/kg, respectively. 2) EGT1442 significantly prolonged the median survival of SHRSP rats. 3) EGT1442 dose-dependently reduced HbA1c and blood glucose concentration without affecting body mass or insulin level.

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02820298 Theracos Type 2 Diabetes Mellitus June 2016 Phase 1
NCT02390050 Theracos Diabetes Mellitus, Type 2 May 2015 Phase 2|Phase 3
NCT02836873 Theracos Type 2 Diabetes Mellitus September 2016 Phase 3
NCT03167411 Theracos Type2 Diabetes Mellitus June 20, 2017 Phase 1
NCT03197324 Theracos Type2 Diabetes Mellitus July 24, 2017 Phase 1
NCT02558296 Theracos Type 2 Diabetes Mellitus October 2015 Phase 3
NCT02715258 Theracos Type 2 Diabetes Mellitus March 2016 Phase 3
NCT02769481 Theracos Type 2 Diabetes Mellitus August 2016 Phase 3
NCT03115112 Theracos Type 2 Diabetes Mellitus August 1, 2017 Phase 3
NCT02956044 Theracos Type2 Diabetes Mellitus November 2016 Phase 1
NCT02820298 Theracos Type 2 Diabetes Mellitus June 2016 Phase 1
NCT02390050 Theracos Diabetes Mellitus, Type 2 May 2015 Phase 2|Phase 3
NCT02836873 Theracos Type 2 Diabetes Mellitus September 2016 Phase 3
NCT03167411 Theracos Type2 Diabetes Mellitus June 20, 2017 Phase 1
NCT03197324 Theracos Type2 Diabetes Mellitus July 24, 2017 Phase 1
NCT02558296 Theracos Type 2 Diabetes Mellitus October 2015 Phase 3
NCT02715258 Theracos Type 2 Diabetes Mellitus March 2016 Phase 3
NCT02769481 Theracos Type 2 Diabetes Mellitus August 2016 Phase 3
NCT03115112 Theracos Type 2 Diabetes Mellitus August 1, 2017 Phase 3
NCT02956044 Theracos Type2 Diabetes Mellitus November 2016 Phase 1
NCT01029704 Theracos Diabetes Mellitus Type 2 December 2009 Phase 2
NCT01377844 Theracos Diabetes Mellitus December 2011 Phase 2
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.1508 mL 10.7541 mL 21.5082 mL
5 mM 0.4302 mL 2.1508 mL 4.3016 mL
10 mM 0.2151 mL 1.0754 mL 2.1508 mL
References
Molecular Weight

464.94

Formula

C₂₄H₂₉ClO₇

CAS No.

1118567-05-7

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Bexagliflozin
Cat. No.:
HY-17604
Quantity: